Vaccinia immune globulin - Emergent BioSolutions

Drug Profile

Vaccinia immune globulin - Emergent BioSolutions

Alternative Names: C-VIG; CNJ 016; VIG; VIGIV - Emergent BioSolutions

Latest Information Update: 03 Sep 2015

Price : $50

At a glance

  • Originator Cangene Corporation
  • Developer Emergent BioSolutions
  • Class Immunoglobulins
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Smallpox

Most Recent Events

  • 13 Aug 2015 US Centers for Disease Control and Prevention exercises options for the supply of vaccinia immune globulin IV into the US Strategic National Stockpile
  • 21 Feb 2014 Cangene Corporation has been acquired and merged into Emergent BioSolutions
  • 29 Aug 2012 Cangene enters into a new contract with the US CDC for the supply of vaccinia immune globulin intravenous into the US Strategic National Stockpile, and for services to support licensure maintenance activities
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top